NASDAQ:SGHT Sight Sciences (SGHT) Stock Price, News & Analysis $4.91 +0.21 (+4.47%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$4.92 +0.01 (+0.31%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sight Sciences Stock (NASDAQ:SGHT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sight Sciences alerts:Sign Up Key Stats Today's Range$4.41▼$4.9450-Day Range$4.34▼$5.8452-Week Range$3.11▼$9.24Volume145,495 shsAverage Volume200,689 shsMarket Capitalization$267.15 millionP/E RatioN/ADividend YieldN/APrice Target$8.25Consensus RatingHold Company Overview Sight Sciences, Inc. is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy. Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model. Its clinical programs have explored both standalone and adjunctive uses of its platforms, seeking to expand indications in glaucoma management and ocular surface disease. The company continues to invest in iterative improvements and new treatment modalities built upon its core thermal and micro-invasive glaucoma surgery (MIGS) technologies. Headquartered in Menlo Park, California, Sight Sciences distributes its products across the United States and has established partnerships to serve markets in Canada, Europe and Australia. The company supports its customers with training programs, surgical support services and a dedicated clinical affairs team to gather real-world evidence and refine procedural protocols. Leadership at Sight Sciences includes President and Chief Executive Officer Gregg Prentice, who brings deep experience in medical device commercialization, and a management team with expertise in ophthalmology, regulatory affairs and commercial operations. The company’s board and executive ranks blend industry veterans with academic researchers, underscoring its commitment to advancing eye care through innovation.AI Generated. May Contain Errors. Read More Sight Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreSGHT MarketRank™: Sight Sciences scored higher than 54% of companies evaluated by MarketBeat, and ranked 291st out of 837 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingSight Sciences has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 5 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialSight Sciences has a consensus price target of $8.25, representing about 68.0% upside from its current price of $4.91.Amount of Analyst CoverageSight Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Sight Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sight Sciences are expected to grow in the coming year, from ($0.60) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sight Sciences is -6.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sight Sciences is -6.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSight Sciences has a P/B Ratio of 4.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sight Sciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.19% of the float of Sight Sciences has been sold short.Short Interest Ratio / Days to CoverSight Sciences has a short interest ratio ("days to cover") of 5.03.Change versus previous monthShort interest in Sight Sciences has recently increased by 14.21%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSight Sciences does not currently pay a dividend.Dividend GrowthSight Sciences does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.62 News SentimentSight Sciences has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Sight Sciences this week, compared to 3 articles on an average week.Search Interest1 people have searched for SGHT on MarketBeat in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sight Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $318,827.00 in company stock.Percentage Held by Insiders30.40% of the stock of Sight Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Sight Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sight Sciences' insider trading history. Receive SGHT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sight Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SGHT Stock News HeadlinesHead-To-Head Review: Integra LifeSciences (NASDAQ:IART) & Sight Sciences (NASDAQ:SGHT)July 24 at 2:58 AM | americanbankingnews.comSight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026July 22 at 4:05 PM | globenewswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.July 25 at 1:00 AM | Base Camp Trading (Ad)Financial Review: ENDRA Life Sciences (NASDAQ:NDRA) versus Sight Sciences (NASDAQ:SGHT)July 15, 2026 | americanbankingnews.comCiti Keeps Their Hold Rating on Sight Sciences (SGHT)July 10, 2026 | theglobeandmail.comInsider Selling: Sight Sciences (NASDAQ:SGHT) EVP Sells 2,829 SharesJuly 7, 2026 | insidertrades.comSGHT Share News TodayJune 18, 2026 | uk.investing.comSight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptMay 13, 2026 | seekingalpha.comSee More Headlines SGHT Stock Analysis - Frequently Asked Questions How have SGHT shares performed this year? Sight Sciences' stock was trading at $7.93 on January 1st, 2026. Since then, SGHT shares have decreased by 38.1% and is now trading at $4.91. How were Sight Sciences' earnings last quarter? Sight Sciences, Inc. (NASDAQ:SGHT) released its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.05. The company had revenue of $19.70 million for the quarter, compared to analysts' expectations of $18.47 million. Sight Sciences had a negative trailing twelve-month return on equity of 52.34% and a negative net margin of 46.83%. Read the conference call transcript. When did Sight Sciences IPO? Sight Sciences (SGHT) raised $235 million in an initial public offering (IPO) on Wednesday, July 14th 2021. The company issued 10,000,000 shares at a price of $23.00-$24.00 per share. How do I buy shares of Sight Sciences? Shares of SGHT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sight Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sight Sciences investors own include American Water Works (AWK), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Waste Connections (WCN), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/06/2026Today7/25/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:SGHT CIK1531177 Webwww.sightsciences.com Phone877-266-1144FaxN/AEmployees210Year Founded2011Price Target and Rating Average Price Target for Sight Sciences$8.25 High Price Target$11.00 Low Price Target$6.00 Potential Upside/Downside+68.0%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.43 million Net Margins-46.83% Pretax Margin-46.85% Return on Equity-52.34% Return on Assets-28.49% Debt Debt-to-Equity Ratio0.68 Current Ratio5.86 Quick Ratio5.48 Sales & Book Value Annual Sales$77.36 million Price / Sales3.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.21 per share Price / Book4.06Miscellaneous Outstanding Shares54,410,000Free Float37,869,000Market Cap$267.15 million OptionableOptionable Beta2.38 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:SGHT) was last updated on 7/25/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...Chaikin Analytics | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely | SponsoredHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sight Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sight Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
